Key clinical point: There was no difference in prostate cancer (PCa)-specific mortality between active surveillance (AS), radical prostatectomy (RP), and radical radiotherapy (RRT) at a median follow-up of 10 years.
Major finding: There were no statistically significant differences between the 3 groups for PCa-specific mortality (P = .48) and all-cause mortality (P = .87). Rates of metastases and disease progression were higher in the AS group than in the RP and RRT groups.
Study details: The ProtecT trial: 1,643 men aged 50-69 years with localized PCa agreed to randomization to AS (n = 545), RP (n = 553), or RRT (n = 545); 997 chose a treatment.
Disclosures: The project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme. Some authors reported ties with multiple pharmaceutical companies. Some authors were a part of other NIHR-funded projects.
Hamdy FC et al. Health Technol Assess. 2020 Aug. doi: 10.3310/hta24370.